Overview

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers

Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
Phase:
Phase 1
Details
Lead Sponsor:
Respirent Pharmaceuticals Co Ltd.
Collaborator:
Becro Ltd.
Treatments:
Fluticasone
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Fluticasone-Salmeterol Drug Combination
Salmeterol Xinafoate
Xhance